Palvella Therapeutics Inc. (NASDAQ: PVLA) announced that the first patients have been dosed in its Phase 2 LOTU clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE